<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Hepatic insulin degradation decreases in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Insulin-degrading enzyme (IDE) plays a key role in insulin degradation and its gene is located in a <z:mp ids='MP_0002055'>diabetes</z:mp>-associated chromosomal region </plain></SENT>
<SENT sid="2" pm="."><plain>We hypothesised that IDE may be regulated by insulin and/or <z:chebi fb="105" ids="17234">glucose</z:chebi> in a liver cell model </plain></SENT>
<SENT sid="3" pm="."><plain>To validate the observed regulation of IDE in vivo, we analysed biopsies of human adipose tissue during different clamp experiments in men </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Human <z:e sem="disease" ids="C0019204" disease_type="Neoplastic Process" abbrv="">hepatoma</z:e> HepG2 cells were incubated in <z:mpath ids='MPATH_458'>normal</z:mpath> (1 g/l) or high (4.5 g/l) <z:chebi fb="105" ids="17234">glucose</z:chebi> medium and treated with insulin for 24 h </plain></SENT>
<SENT sid="5" pm="."><plain>Catalytic activity, <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein levels of IDE were assessed </plain></SENT>
<SENT sid="6" pm="."><plain>IDE <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels were measured in biopsies of human subcutaneous adipose tissue before and at 240 min of hyperinsulinaemic, euglycaemic and hyperglycaemic clamps </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: In HepG2 cells, <z:e sem="disease" ids="C0020459" disease_type="Disease or Syndrome" abbrv="">insulin increased</z:e> IDE activity under <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> conditions with no change in IDE <z:chebi fb="2" ids="33699">mRNA</z:chebi> or protein levels </plain></SENT>
<SENT sid="8" pm="."><plain>Under conditions of high <z:chebi fb="105" ids="17234">glucose</z:chebi>, <z:e sem="disease" ids="C0020459" disease_type="Disease or Syndrome" abbrv="">insulin increased</z:e> <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels of IDE without changes in IDE activity </plain></SENT>
<SENT sid="9" pm="."><plain>Both in <z:mpath ids='MPATH_458'>normal</z:mpath> and high <z:chebi fb="105" ids="17234">glucose</z:chebi> medium, <z:e sem="disease" ids="C0020459" disease_type="Disease or Syndrome" abbrv="">insulin increased</z:e> levels of the catalytically more active 15a IDE isoform compared with the 15b isoform </plain></SENT>
<SENT sid="10" pm="."><plain>In subcutaneous adipose tissue, IDE <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels were not significantly upregulated after euglycaemic or hyperglycaemic clamps </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS/INTERPRETATION: Insulin increases IDE activity in HepG2 cells in <z:mpath ids='MPATH_458'>normal</z:mpath> but not in high <z:chebi fb="105" ids="17234">glucose</z:chebi> conditions </plain></SENT>
<SENT sid="12" pm="."><plain>This disturbance cannot be explained by corresponding alterations in IDE protein levels or IDE splicing </plain></SENT>
<SENT sid="13" pm="."><plain>The loss of insulin-induced regulation of IDE activity under <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> may contribute to the reduced insulin extraction and peripheral <z:e sem="disease" ids="C0020459" disease_type="Disease or Syndrome" abbrv="">hyperinsulinaemia</z:e> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>